GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytophage Technologies Ltd (TSXV:CYTO) » Definitions » Inventories, Other

Cytophage Technologies (TSXV:CYTO) Inventories, Other : C$0.00 Mil (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Cytophage Technologies Inventories, Other?

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. Cytophage Technologies's other inventories for the quarter that ended in Sep. 2024 was C$0.00 Mil.


Cytophage Technologies Inventories, Other Historical Data

The historical data trend for Cytophage Technologies's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytophage Technologies Inventories, Other Chart

Cytophage Technologies Annual Data
Trend Dec21 Dec22 Dec23
Inventories, Other
- - -

Cytophage Technologies Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Inventories, Other Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cytophage Technologies Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.


Cytophage Technologies Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
26 Henlow Bay, Winnipeg, MB, CAN, R3Y 1G4
Cytophage Technologies Ltd is a Canadian biotechnology company that uses molecular genetic techniques and synthetic biology to create effective bacteriophages to address bacterial challenges affecting animal health, human health, and food security. Bacteriophages are viruses that have evolved to specifically target and destroy strictly bacterial cells and are safe for humans, animals, and plants. To combat dangerous bacteria company generates phages to address specific bacterial infections, including strains resistant to antibiotics. It has also developed a 'phage-display' methodology to develop vaccine-like products using bacteriophages for a number of potential applications in human and animal health.